Jim Simons Connect Biopharma Holdings LTD Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Connect Biopharma Holdings LTD stock. As of the latest transaction made, Renaissance Technologies LLC holds 212,300 shares of CNTB stock, worth $222,915. This represents 0.0% of its overall portfolio holdings.

Number of Shares

212,300

Previous 239,900 11.5%

Holding current value

$222,915

Previous $417,000 22.78%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$1.28 - $2.2 $35,328 - $60,720	-27,600 Reduced 11.5%	212,300 $322,000
Q1 2024 May 13, 2024	SELL	$1.01 - $1.74 $58,681 - $101,094	-58,100 Reduced 19.5%	239,900 $417,000
Q4 2023 Feb 13, 2024	BUY	$0.7 - $2.06 $140,700 - $414,060	201,000 Added 207.22%	298,000 $352,000
Q3 2023 Nov 14, 2023	BUY	$0.65 - $1.18 $975 - $1,770	1,500 Added 1.57%	97,000 $79,000
Q2 2023 Aug 11, 2023	BUY	$1.01 - $1.25 $6,464 - $8,000	6,400 Added 7.18%	95,500 $108,000
Q1 2023 May 12, 2023	BUY	$0.82 - $1.32 $4,264 - $6,864	5,200 Added 6.2%	89,100 $89,000
Q4 2022 Feb 13, 2023	BUY	$0.64 - $1.31 $384 - $786	600 Added 0.72%	83,900 $73,000
Q3 2022 Nov 14, 2022	BUY	$0.8 - $1.65 $13,120 - $27,060	16,400 Added 24.51%	83,300 $107,000
Q2 2022 Aug 12, 2022	BUY	$0.56 - $3.25 $24,304 - $141,050	43,400 Added 184.68%	66,900 $58,000
Q1 2022 May 13, 2022	BUY	$2.46 - $5.92 $31,242 - $75,184	12,700 Added 117.59%	23,500 $71,000
Q4 2021 Feb 11, 2022	BUY	$4.26 - $23.33 $46,008 - $251,963	10,800 New	10,800 $56,000

Others Institutions Holding CNTB

# of Institutions

Shares Held

3.03M

Call Options Held

Put Options Held

View Full List

About Connect Biopharma Holdings Ltd

Ticker CNTB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,015,800
Market Cap $57.8M
Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for t...

More about CNTB

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account